1 |
Xiang L, Li Y, Gu X, Li S, Li J, Li J, Yi Y. Nucleolin recognizing silica nanoparticles inhibit cell proliferation by activating the Bax/Bcl-2/caspase-3 signalling pathway to induce apoptosis in liver cancer. Front Pharmacol 2023;14:1117052. [PMID: 36843953 DOI: 10.3389/fphar.2023.1117052] [Reference Citation Analysis]
|
2 |
Liu Y, Yang H, Xiong J, Zhao J, Guo M, Chen J, Zhao X, Chen C, He Z, Zhou Y, Xu L. Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective. Biomed Pharmacother 2023;157:113991. [PMID: 36370524 DOI: 10.1016/j.biopha.2022.113991] [Reference Citation Analysis]
|
3 |
Lu Y, Gao Y, Yang H, Hu Y, Li X. Nanomedicine-boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma. Mil Med Res 2022;9:69. [PMID: 36503490 DOI: 10.1186/s40779-022-00433-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
4 |
Yang C, Jin YY, Mei J, Hu D, Jiao X, Che HL, Tang CL, Zhang Y, Wu GS. Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis. Cancer Cell Int 2022;22:202. [PMID: 35642041 DOI: 10.1186/s12935-022-02621-y] [Reference Citation Analysis]
|
5 |
Sun J, Wang J, Li T, Ma Y, Xue D, Chen J. Design and synthesis of ludartin derivatives as potential anticancer agents against hepatocellular carcinoma. Med Chem Res. [DOI: 10.1007/s00044-022-02890-2] [Reference Citation Analysis]
|
6 |
Li K, Xiao K, Zhu S, Wang Y, Wang W. Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges. Front Pharmacol 2022;13:889799. [DOI: 10.3389/fphar.2022.889799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|